Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 6, 2026, 4:03 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 788 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: SCD Clear all
Completed Phase 2 Interventional

A Study of HQK-1001 in Patients With Sickle Cell Disease

NCT01322269
View directory record Official record
Conditions
Sickle Cell Disease, Sickle Cell Anemia, Sickle Cell Disorders, Hemoglobin S Disease, Sickling Disorder Due to Hemoglobin S
Interventions
HQK-1001
Drug
Lead sponsor
HemaQuest Pharmaceuticals Inc.
Industry
Eligibility
12 Years to 60 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
9
States / cities
Oakland, California • Miami, Florida • Augusta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2013 · Synced Sep 6, 2026, 4:03 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Ketamine Infusion for Acute Sickle Cell Crisis in the Emergency Department

NCT02417298
View directory record Official record
Conditions
Pain, Sickle Cell Disorder
Interventions
Normal saline, Ketamine
Drug
Lead sponsor
Billy Sin
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated May 10, 2018 · Synced Sep 6, 2026, 4:03 AM EDT
Terminated Phase 3 Interventional

A Study to Evaluate the Long-term Safety of Inclacumab Administered to Participants With Sickle Cell Disease

NCT05348915
View directory record Official record
Conditions
Sickle Cell Disease, Vaso-occlusive Crisis, Vaso-occlusive Pain Episode in Sickle Cell Disease
Interventions
Inclacumab
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years and older
Enrollment
242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
18
States / cities
Mobile, Alabama • Little Rock, Arkansas • Orange, California + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Sep 6, 2026, 4:03 AM EDT
Terminated Phase 2 Interventional Results available

Feasibility Study of Unfractionated Heparin in Acute Chest Syndrome

NCT02098993
View directory record Official record
Conditions
Acute Chest Syndrome, Sickle Cell Disease
Interventions
Unfractionated heparin
Drug
Lead sponsor
Craig Seaman
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 15, 2019 · Synced Sep 6, 2026, 4:03 AM EDT
Completed Phase 2 Interventional

Research Study Investigating How Well NDec Works in People With Sickle Cell Disease

NCT05405114
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
NDec - oral decitabine-tetrahydrouridine, HU - Hydroxyurea, Placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
53
States / cities
Mobile, Alabama • Los Angeles, California • Oakland, California + 37 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Sep 6, 2026, 4:03 AM EDT
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

Cor360: Clinician-Facing Broad-Spectrum Cardiac Phenotyping and Risk Assessment Using COR® Wearable ECG to Inform Outcomes-Oriented Care Pathways

NCT07775976
View directory record Official record
Conditions
Cardiovascular Diseases, Cardiovascular Diseases Risk, Cardiac Conduction System Disease, Bundle/Fascicular Abnormalities, His-Purkinje Disease, Arrhythmias, Cardiac, Rhythm Phenotypes, Myocardial Ischemia, Syncope, Syncope Recurrent, Syncope and Collapse, Seizure Disorder, Sleep Apnea Syndrome, Obstructive, Decision Support Systems, Clinical, Heart Failure - NYHA II - IV, Heart Failure (for Example, Fluid Overload), HRV, Cardiopulmonary, Sudden Cardiac Arrest, Cardiac Arrest (CA), Ventricular Arrhythmias and Cardiac Arrest, Ventricular Fibrillation, QT Dispersion, Atrial Cardiomyopathy
Interventions
COR Wearable ECG Monitoring, Cor360 Clinician-Facing Decision-Aid Reporting
Device · Other
Lead sponsor
Peerbridge Health, Inc
Industry
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
2
States / cities
Pasadena, California • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Sep 6, 2026, 4:03 AM EDT
Terminated Phase 3 Interventional Results available

A Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants With Sickle Cell Disease and Recurrent Vaso-occlusive Crises

NCT04927247
View directory record Official record
Conditions
Sickle Cell Disease, Vaso-occlusive Crisis, Vaso-occlusive Pain Episode in Sickle Cell Disease
Interventions
Inclacumab, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
17
States / cities
Mobile, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 11 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2024 · Synced Sep 6, 2026, 4:03 AM EDT
Completed No phase listed Observational Results available

Priapism in Boys and Men With Sickle Cell Disease - Demographics, Characteristics and Prevalence

NCT00300235
View directory record Official record
Conditions
Priapism, Anemia, Sickle Cell
Interventions
Not listed
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
5 Years and older · Male only
Enrollment
1,464 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
27
States / cities
Mobile, Alabama • Davis, California • Oakland, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2019 · Synced Sep 6, 2026, 4:03 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

Non-myeloablative Haploidentical HCT Study for Patients With Sickle Cell Disease, Including Compromised Organ Function

NCT06145282
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Briquilimab, Filgrastim, Abatacept, Sirolimus, Cyclophosphamide
Biological · Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
4 Years to 100 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Sep 6, 2026, 4:03 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of MitoQ on Platelet Function and Reactive Oxygen Species Generation in Patients With Sickle Cell Anemia

NCT04109820
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
MitoQ
Dietary Supplement
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2025
U.S. locations
5
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Sep 6, 2026, 4:03 AM EDT
Completed No phase listed Observational

Validation of the Sickle Cell Disease Pain Burden Interview

NCT00804362
View directory record Official record
Conditions
Sickle Cell Disease, Pain
Interventions
Not listed
Lead sponsor
Connecticut Children's Medical Center
Other
Eligibility
7 Years to 21 Years
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 29, 2013 · Synced Sep 6, 2026, 4:03 AM EDT
Terminated Phase 1Phase 2 Interventional

A Voxelotor for Sickle Cell Anemia Patients at Highest Risk for Progression of Chronic Kidney Disease

NCT04335721
View directory record Official record
Conditions
Sickle Cell Disease, Sickle Cell Nephropathy
Interventions
Voxelotor
Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 2, 2025 · Synced Sep 6, 2026, 4:03 AM EDT
Terminated Phase 1Phase 2 Interventional

Gene Transfer for Patients With Sickle Cell Disease

NCT02186418
View directory record Official record
Conditions
Anemia, Sickle Cell
Interventions
ARU-1801
Genetic
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
18 Years to 45 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 11, 2024 · Synced Sep 6, 2026, 4:03 AM EDT
Not listed No phase listed Observational

Sickle Cell Anemia - A Comparative Study Between Three Ethnical Communities, a Multicenter Study

NCT01905787
View directory record Official record
Conditions
Sickle Cell Anemia, Sickle Cell β+ or β0 Thalassemia
Interventions
Not listed
Lead sponsor
HaEmek Medical Center, Israel
Other
Eligibility
1 Year to 40 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 30, 2019 · Synced Sep 6, 2026, 4:03 AM EDT
Completed Phase 3 Interventional

Evaluation of Repeat Administration of Purified Poloxamer 188

NCT02449616
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
MST-188
Drug
Lead sponsor
Mast Therapeutics, Inc.
Industry
Eligibility
4 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2015
U.S. locations
9
States / cities
San Diego, California • Fort Myers, Florida • Hollywood, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2016 · Synced Sep 6, 2026, 4:03 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Functional Ovarian Reserve in Sickle Cell Disease

NCT07392216
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Not listed
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
10 Years to 18 Years · Female only
Enrollment
440 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2034
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Sep 6, 2026, 4:03 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Evaluation of the OsciPulse Rapid Cycling Compression Device Effects on Venous Blood Flow

NCT05087108
View directory record Official record
Conditions
Venous Thromboses, Venous Stasis
Interventions
OsciPulse system, Reference Therapy 1, Refence Therapy 2
Device
Lead sponsor
OsciFlex LLC
Industry
Eligibility
40 Years to 90 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 8, 2023 · Synced Sep 6, 2026, 4:03 AM EDT
Temporarily Not Available No phase listed Expanded access

Expanded Access Protocol for Gene Therapy Utilizing shmiR Lentivirus Vector to Induce Fetal Hemoglobin in Sickle Cell Disease

NCT07640815
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Autologous CD34+ HSC cells transduced with the lentiviral vector containing a shRNA targeting BCL11a
Biological
Lead sponsor
David Williams
Other
Eligibility
13 Years to 55 Years
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Sep 6, 2026, 4:03 AM EDT
Completed Phase 1 Interventional Results available

Biotin-RBC Transfusion in SCD

NCT04426591
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Biotin Labeled Red Blood Cells, Pathogen-reduced Biotin Labeled Red Blood Cells
Drug · Device
Lead sponsor
Marianne Yee
Other
Eligibility
2 Years to 65 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
3
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Sep 6, 2026, 4:03 AM EDT
Not listed Not applicable Interventional

SCD vs. Mediterranean Diet Therapy in Ulcerative Colitis

NCT04398550
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Specific Carbohydrate Diet, Mediterranean Diet
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 30, 2022 · Synced Sep 6, 2026, 4:03 AM EDT
Completed Phase 2 Interventional Results available

Evaluating the Safety and Effectiveness of Bone Marrow Transplants in Children With Sickle Cell Disease (BMT CTN 0601)

NCT00745420
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Hematopoietic Stem Cell Transplantation
Biological
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
3 Years to 19 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
19
States / cities
Birmingham, Alabama • Washington D.C., District of Columbia • Miami, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2022 · Synced Sep 6, 2026, 4:03 AM EDT
Recruiting Phase 1Phase 2 Interventional

Cannabidiol in Sickle Cell Disease

NCT06930703
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Cannabidiol, Placebo
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Manhattan, New York
Source: ClinicalTrials.gov public record
Updated Jun 24, 2025 · Synced Sep 6, 2026, 4:03 AM EDT
Completed No phase listed Observational

Psychometric Evaluation of the IPPAQ in Pediatric Patients With Sickle Cell Disease Hospitalized With Vasoocclusive Pain

NCT01058473
View directory record Official record
Conditions
Sickle Cell Disease, Pain
Interventions
Not listed
Lead sponsor
Connecticut Children's Medical Center
Other
Eligibility
7 Years to 21 Years
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 29, 2013 · Synced Sep 6, 2026, 4:03 AM EDT
Completed Not applicable Interventional

Preliminary Feasibility and Efficacy of Behavioral Intervention to Reduce Pain-Related Disability in Pediatric SCD

NCT04388241
View directory record Official record
Conditions
Sickle Cell Disease, Pain
Interventions
The Balance Program
Behavioral
Lead sponsor
Children's National Research Institute
Other
Eligibility
8 Years to 17 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Sep 5, 2022 · Synced Sep 6, 2026, 4:03 AM EDT